Vivek Subbiah/LinkedIn
Jun 23, 2025, 06:04
Vivek Subbiah: Reflecting on a Successful ASCO and the Bright Future of Cancer Treatment
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Another incredible ASCO in the books. So proud to see the team work across multiple tumor types and oncology areas featured this year. Huge thanks to the patients, collaborators, and colleagues who make this progress possible. We’re just getting started; the future of cancer treatment is bright. Check out Dr. David R. Spigel thoughtful reflections below.”
David R. Spigel, Chief Scientific Officer at Sarah Cannon Research Institute, shared a post on LinkedIn:
“ASCO 2025 was a fantastic meeting for progress in research and education.
Our team at Sarah Cannon Research Institute plays an integral role in this work, collaborating with colleagues across the world. The excitement of new breakthroughs in care and emerging data in both advanced and early-stage settings motivates all of us to work harder and faster. There’s still so much to do, but we see continued gains and opportunities ahead.”
More posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 07:59
Jun 23, 2025, 07:42
Jun 23, 2025, 07:30